We are thrilled to announce a strategic move. Effective immediately, hinlab SAS has transitioned to a subsidiary of hinlab Inc., headquartered in Delaware, United States.
This “flip” positions the company to leverage the dynamic U.S. medical device market while maintaining its strong roots in Europe. With its headquarters now based in Delaware, hinlab gains strategic advantages, including access to a robust ecosystem of investors, customers, and talent, further fueling its growth trajectory.
This transformation underscores hinlab’s dedication to advancing research and development (R&D) initiatives. By retaining its R&D center in Paris, hinlab continues to harness the rich pool of talent and expertise in one of Europe’s thriving technology hubs.
hinlab extends its deepest gratitude to its investors whose unwavering support has been instrumental in driving this transformation. Their confidence and belief in hinlab’s vision have played a pivotal role in facilitating this strategic move.
Furthermore, hinlab acknowledges the invaluable assistance provided by Goodwin LLP in navigating the legal intricacies of this transition. Their expertise and guidance have been integral in ensuring a seamless and efficient process, allowing hinlab to achieve a change that very few startups succeed at. This is particularly true for those at advanced stages, like hinlab, with established capital structure, major partnerships and a patent portfolio. The “Delaware flip” process requires extensive time and resources from management, shareholders, and professional advisors.
With a strengthened presence in the United States and a thriving R&D center in Paris, hinlab is poised to keep creating more value for its investors.
